Synapse - Genitourinary Oncology Service

Results (5695)

Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial

Meeting Abstract

Grivas, P.; Loriot, Y.; Feyerabend, S.; Morales-Barrera, R.; Teo, M. Y.; Vogelzang, N. J.; Grande, E.; Zakharia, Y.; Adra, N.; Alva, A. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer

Meeting Abstract

Hoimes, C. J.; Rosenberg, J. E.; Petrylak, D. P.; Carret, A. S.; Sasse, C.; Chaney, M. F.; Flaig, T. W.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Causes and patterns of mortality in patients with lethal germ cell tumor (GCT)

Meeting Abstract

Hamid, A.; Funt, S. A.; Markt, S. C.; Bromberg, M.; O'Donnell, D.; Adra, N.; Taza, F.; Albany, C.; Krailo, M. D.; Frazier, A. L.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Response to systemic therapy in patients with metastatic fumarate hydratase (FH) deficient renal cell carcinoma (RCC)

Meeting Abstract

Gleeson, J. P.; Nikolovski, I.; Kotecha, R.; Ged, Y.; Shapnik, N.; Knezevic, A.; Feldman, D. R.; Lee, C. H.; Voss, M. H.; Chen, Y. B.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest?

Meeting Abstract

Drago, J. Z.; Kantoff, P. W.; Stopsack, K. H.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Differential expression of melanoma-associated antigen A3/6 and associated immune molecules prior to and post treatment with immune checkpoint inhibitors (ICI) in patients with mUC

Meeting Abstract

Faiena, I.; Funt, S. A.; Astrow, S. H.; Dorff, T. B.; Adhikary, S.; Gorgan, T.; Rosenberg, J. E.; Elashoff, D.; Pantuck, A. J.; Drakaki, A.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Knezevic, A.; Wilson, K.; Bromberg, M.; Budnick, A.; McHugh, D. J.; Larsen, E.; Bajorin, D. F.; Motzer, R. J.; Tonorezos, E. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Genomic determinants of nested variant urothelial carcinoma

Meeting Abstract

Clinton, T. N.; Whiting, K.; Silva, V.; Li, Q.; Almassi, N.; Pietzak, E.; Bagrodia, A.; Cha, E. K.; Dalbagni, G.; Iyer, G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Defining the genetic evolution of epigenetic alterations in bladder cancer

Meeting Abstract

Clinton, T. N.; Wise, H.; Almassi, N.; Chavan, S. S.; Hu, W.; Gao, S. P.; Hanrahan, A.; Dason, S.; Pietzak, E. J.; Carlo, M. I.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Meeting Abstract

Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P. R.; Dunshee, C.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save